Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Timber Pharmaceuticals, Inc. | bpmx-20170131ex321e50e27.htm |
| 10-K - 10-K - Timber Pharmaceuticals, Inc. | bpmx-20170131x10k.htm |
| EX-31.2 - EX-31.2 - Timber Pharmaceuticals, Inc. | bpmx-20170131ex3129e78bc.htm |
| EX-31.1 - EX-31.1 - Timber Pharmaceuticals, Inc. | bpmx-20170131ex3110faf1f.htm |
| EX-21.1 - EX-21.1 - Timber Pharmaceuticals, Inc. | bpmx-20170131ex2115e288a.htm |
| EX-10.23 - EX-10.23 - Timber Pharmaceuticals, Inc. | bpmx-20170131ex102379071.htm |
| EX-10.11 - EX-10.11 - Timber Pharmaceuticals, Inc. | bpmx-20170131ex10117bf7f.htm |
| EX-3.5 - EX-3.5 - Timber Pharmaceuticals, Inc. | bpmx-20170131ex359e7e407.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-213627 and 333-201708) and the Registration Statements on Form S-3 (No. 333-213635, 333-212015, and 333-209026) of BioPharmX Corporation of our report (which contains an explanatory paragraph relating to BioPharmX Corporation’s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) dated April 21, 2017 relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.
/s/ BPM LLP
San Jose, California
April 21, 2017